在子宫内膜癌中HER2评分系统的比较:向优化HER2导向疗法的方向
Ekaterina Menshikova1, Kristin Deeb1, Elizabeth M Genega1
1Department of Pathology and Laboratory Medicine, Emory University Hospital, Emory University School of Medicine, Atlanta, GA.
The American journal of surgical pathology
|March 26, 2025
概括
在子宫内膜癌 (EC) 中HER2测试对于向治疗至关重要. 不同的评分标准 (妇科,胃,乳腺) 产生不同的HER2阳性率,影响治疗决策.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 遗传学 是一个遗传学.
背景情况:
- 子宫内膜癌 (EC) 呈现出可变的HER2表达,使其成为HER2导向疗法的候选人,如trastuzumab和抗体-药物结合体 (ADCs).
- 目前的HER2测试建议侧重于晚期/复发的血清性癌和癌瘤,但缺乏标准化的报告准则,导致机构实践不一致.
研究的目的:
- 分析欧洲共同体在HER2测试方面的机构经验.
- 在EC中比较妇科 (GyC),胃 (GaC) 和乳腺 (BrC) HER2评分标准的表现.
主要方法:
- 具有可用的HER2免疫组织化学 (IHC) 和光现场杂交 (FISH) 结果的EC病例的回顾性鉴定.
- 使用GyC,GaC和BrC评分系统重新评估HER2 IHC.
- 统计分析用于比较分数系统之间的一致率.
主要成果:
- 根据GyC和BrC标准,总体HER2阳性率为31%,根据GaC标准为35.7%.
- 在评分结果中观察到显著差异,GaC和GyC之间的一致性为69.8% (P<0.001).
- 在BrC和GyC标准之间发现了很高的一致性 (99.2%).
结论:
- 选择HER2评分标准显著影响了欧洲共同体的HER2阳性率.
- 适当的HER2评分标准的选择和应用对于指导HER2导向治疗决策至关重要.
- 清楚而全面地报告HER2状态对于优化EC患者的临床结果至关重要.
更多相关视频
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.4K
08:29Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
53
相关概念视频
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...